1. Volume 71, Issue 5, Pages 838-840 (May 2017)
How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? 
Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, Outi Hirvonen, Tarja Laitinen, Sirkku Jyrkkiö, Laura L. Elo 
European Urology 
Volume 71, Issue 5, Pages (May 2017)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
(A) Principal component analysis of the four randomized clinical trial datasets ASCENT2 (n=476), MAINSAIL (n=526), VENICE (n=598), ENTHUSE 33 (n=470), and the real-world (RW) cohort (n=289). Principal component analysis was performed using the variables from the Halabi model, including analgesic use, metastasis site (defined as lymph node only, bone metastases with no visceral involvement, or any visceral metastases), Eastern Cooperative Oncology Group performance status, lactate dehydrogenase, albumin, hemoglobin, alkaline phosphatase, and prostate-specific antigen. (B) Performance of the selected four models in the RW cohort (Turku University Hospital, Finland, n=289) and (C) the randomized clinical trial validation cohort (ENTHUSE 33, n=313). The ENTHUSE trial included 470 patients of which 313 patients were used as the final method evaluation in the Dialogue for Reverse Engineering Assessments and Methods Challenge. The performance of the models in predicting the overall survival at different time points was measured using the time-dependent area under the curve (AUC) from 6 mo to 30 mo with 1-mo intervals.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions